Search research articles
Contact Us
Filters
Showing results (71-80 of 83) with videos related to
Page
of 9
Sort By:
International Journal of Radiation Oncology, Biology, Physics
|
May 15, 2002
Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas
V A Levin, W K A Yung, J Bruner, et al.
Clinical Radiology
|
April 2, 2022
The ins and outs of male breast and anterior chest wall lesions from childhood to adulthood
S Yang, Y Leng, C M Chau, et al.
Journal of Neuro-Oncology
|
June 27, 2008
Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma
J F de Groot, M R Gilbert, K Aldape, et al.
Molecular Psychiatry
|
July 13, 2016
Lithium suppression of tau induces brain iron accumulation and neurodegeneration
P Lei, S Ayton, A T Appukuttan, et al.
Neuro-Oncology
|
March 15, 2006
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study
Michael D Prados, Kathleen Lamborn, W K A Yung, et al.
Cell Reports
|
November 30, 2017
Testosterone Attenuates Group 2 Innate Lymphoid Cell-Mediated Airway Inflammation
Jacqueline-Yvonne Cephus, Matthew T Stier, Hubaida Fuseini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 3, 2011
Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept
John F de Groot, Yuji Piao, Hai Tran, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 11, 2021
Prognostic Significance of IDH1/2 Mutation and MGMT Promoter Methylation Status in RTOG 9813
J L Fleming, S Pugh, E H Bell, et al.
Neuro-Oncology
|
February 11, 2004
Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study
Michael D Prados, W K A Yung, Kurt A Jaeckle, et al.
Schizophrenia Research
|
October 23, 2017
The Ultra-High-Risk for psychosis groups: Evidence to maintain the status quo
M J McHugh, P D McGorry, H P Yuen, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 83) with videos related to
Sort By:
Page
of 9
International Journal of Radiation Oncology, Biology, Physics
|
May 15, 2002
Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas
V A Levin, W K A Yung, J Bruner, et al.
Clinical Radiology
|
April 2, 2022
The ins and outs of male breast and anterior chest wall lesions from childhood to adulthood
S Yang, Y Leng, C M Chau, et al.
Journal of Neuro-Oncology
|
June 27, 2008
Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma
J F de Groot, M R Gilbert, K Aldape, et al.
Molecular Psychiatry
|
July 13, 2016
Lithium suppression of tau induces brain iron accumulation and neurodegeneration
P Lei, S Ayton, A T Appukuttan, et al.
Neuro-Oncology
|
March 15, 2006
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study
Michael D Prados, Kathleen Lamborn, W K A Yung, et al.
Cell Reports
|
November 30, 2017
Testosterone Attenuates Group 2 Innate Lymphoid Cell-Mediated Airway Inflammation
Jacqueline-Yvonne Cephus, Matthew T Stier, Hubaida Fuseini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 3, 2011
Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept
John F de Groot, Yuji Piao, Hai Tran, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 11, 2021
Prognostic Significance of IDH1/2 Mutation and MGMT Promoter Methylation Status in RTOG 9813
J L Fleming, S Pugh, E H Bell, et al.
Neuro-Oncology
|
February 11, 2004
Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study
Michael D Prados, W K A Yung, Kurt A Jaeckle, et al.
Schizophrenia Research
|
October 23, 2017
The Ultra-High-Risk for psychosis groups: Evidence to maintain the status quo
M J McHugh, P D McGorry, H P Yuen, et al.
Page
of 9